Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04229225 · ClinicalTrials.gov registry record · Phase 1
A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee
A Phase 1 study, sponsored by Unity Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT04229225 is a Phase 1 study that has completed, run by Unity Biotechnology. The registered enrollment target is 35 participants.
The verdict
NCT04229225, a Phase 1 study, has completed, sponsored by Unity Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
A study to assess safety, tolerability and clinical effects of single and repeat dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
Interventions
- OTHER Placebo
- DRUG UBX0101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2020-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04229225
The ClinicalTrials.gov registry entry for NCT04229225 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Unity Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04229225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04229225 about?
NCT04229225 is a clinical study titled "A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee". A study to assess safety, tolerability and clinical effects of single and repeat dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
What is the current status of trial NCT04229225?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2020-01-23. Estimated completion is 2020-09-18.
What interventions are being tested in trial NCT04229225?
The interventions under investigation include: Placebo (OTHER), UBX0101 (DRUG).
Who is sponsoring clinical trial NCT04229225?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.